Predictors of ASDAS-CRP inactive disease in axial spondyloarthritis during treatment with TNF-inhibitors: Data from the EuroSpA collaboration

Lykke M. Ørnbjerg; Louise Linde; Stylianos Georgiadis; Simon H. Rasmussen; Ulf Lindström; Johan Askling; Brigitte Michelsen; Daniela Di Giuseppe; Johan K. Wallman; Karel Pavelka; Jakub Závada; Michael J. Nissen; Gareth T. Jones; Heikki Relas; Laura Pirilä; Matija Tomšič; Ziga Rotar; Arni Jon Geirsson; Bjorn Gudbjornsson; Eirik K. Kristianslund; Irene van sder Horst-Bruinsma; Anne Gitte Loft; Karin Laas; Florenzo Iannone; Addolorata Corrado; Adrian Ciurea; Maria J. Santos; Helena Santos; Catalin Codreanu; Nurullah Akkoc; Ozgul S. Gunduz; Bente Glintborg; Mikkel Østergaard; Merete Lund Hetland

doi:10.1016/j.semarthrit.2022.152081

Predictors of ASDAS-CRP inactive disease in axial spondyloarthritis during treatment with TNF-inhibitors: Data from the EuroSpA collaboration

Lykke M. Ørnbjerg
, Louise Linde^* (Corresponding Author)
, Stylianos Georgiadis
, Simon H. Rasmussen
, Ulf Lindström
, Johan Askling
, Brigitte Michelsen
, Daniela Di Giuseppe
, Johan K. Wallman
, Karel Pavelka
, Jakub Závada
, Michael J. Nissen
, Gareth T. Jones
, Heikki Relas
, Laura Pirilä
, Matija Tomšič
, Ziga Rotar
, Arni Jon Geirsson
, Bjorn Gudbjornsson
, Eirik K. Kristianslund

Irene van sder Horst-Bruinsma, Anne Gitte Loft, Karin Laas, Florenzo Iannone, Addolorata Corrado, Adrian Ciurea, Maria J. Santos, Helena Santos, Catalin Codreanu, Nurullah Akkoc, Ozgul S. Gunduz, Bente Glintborg, Mikkel Østergaard, Merete Lund Hetland

^*Corresponding author for this work

University of Copenhagen
University of Gothenburg
Karolinska Institutet
Diakonhjemmet Hospital
Hospital of Southern Norway Trust
Lund University
Institute of rheumatology
Charles University
University of Geneva
Helsinki University Hospital
University of Turku
University of Ljubljana
University Medical Centre Ljubljana
Landspitali University Hospital
University of Iceland
University Medical Center, Radboud
Aarhus University
East-Tallinn Central Hospital
University of Bari
University of Foggia
University Hospital of Zürich
Hospital Garcia de Orta
Sociedade Portuguesa de Reumatologia
Portuguese Institute of Rheumatology
NOVA University Lisbon
Carol Davila University of Medicine and Pharmacy
Manisa Celal Bayar University
Rigshospitalet, Copenhagen
University of Helsinki
Turku University Hospital
University Medical Centre Ljubljana
Aarhus University Hospital
Rigshospitalet

Research output: Contribution to journal › Article › peer-review

25 Citations (Scopus)

7 Downloads (Pure)

Abstract

Objectives: In patients with axial spondyloarthritis (axSpA) initiating their first tumor necrosis factor alpha-inhibitor (TNFi), we aimed to identify common baseline predictors of Ankylosing Spondylitis Disease Activity Score (ASDAS-CRP) inactive disease (primary objective) and clinically important improvement (CII) at 6 months, and drug retention at 12-months across 15 European registries. Methods: Baseline demographic and clinical characteristics were collected. Outcomes were investigated per registry and in pooled data using logistic regression analyses on multiply imputed data. Results: The consistency of baseline predictors in individual registries justified pooling the data. In the pooled dataset (n = 21,196), the 6-month rates for ASDAS inactive disease and ASDAS CII were 26% and 51%, and the 12-month drug retention rate 65% in patients with available data (n = 9,845, n = 6,948 and n = 21,196, respectively). Nine common baseline predictors of ASDAS inactive disease, ASDAS CII and 12-month drug retention were identified, and the odds ratios (95%-confidence interval) for ASDAS inactive disease were: age, per year: 0.97 (0.97–0.98), men vs. women: 1.88 (1.60–2.22), current vs. non-smoking: 0.76 (0.63–0.91), HLA-B27 positive vs. negative: 1.51 (1.20–1.91), TNF start year 2015–2018 vs. 2009–2014: 1.24 (1.06–1.45), CRP>10 vs. ≤10 mg/l: 1.49 (1.25–1.77), one unit increase in health assessment questionnaire (HAQ): 0.77 (0.58–1.03), one-millimeter (mm) increase in Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) fatigue and spinal pain: 0.99 (0.99–1.00) and 0.99 (0.99–1.99), respectively Conclusion: Common baseline predictors of treatment response and adherence to TNFi could be identified across data from 15 European registries, indicating that they may be universal across different axSpA populations.

Original language	English
Article number	152081
Number of pages	13
Journal	Seminars in arthritis and rheumatism
Volume	56
Early online date	17 Aug 2022
DOIs	https://doi.org/10.1016/j.semarthrit.2022.152081 https://doi.org/10.1016/j.semarthrit.2022.152141
Publication status	Published - 1 Oct 2022

Bibliographical note

Funding Information
This work was supported by Novartis Pharma AG .

Acknowledgments
The EuroSpA Research Collaboration Network was financially supported by Novartis Pharma AG. Novartis had no influence on the data collection, statistical analyses, manuscript preparation or decision to submit the manuscript. Professor Gary Macfarlane (University of Aberdeen) is Chief Investigator of BSRBR-AS and facilitated access to the UK data used in this study.

Corrigendum to ‘Predictors of ASDAS-CRP inactive disease in axial spondyloarthritis during treatment with TNF-inhibitors: data from the EuroSpA collaboration’ [Seminars in Arthritis and Rheumatism 56 (2022) 1-13/152081]
https://doi.org/10.1016/j.semarthrit.2022.152141

Data Availability Statement

The data in this article was collected in the individual registries and made available for secondary use through the EuroSpA Research Collaboration Network [https://eurospa.eu/#registries] Relevant patient level data may be made available on reasonable request to the corresponding author, but will require approval from all contributing registries.

Supplementary material associated with this article can be found, in the online version, at doi:10.1016/j.semarthrit.2022.152081.

Funding

LMØ, LL, SG and SHR: research grants from Novartis; UL: none; DDG none; JKW: consultant of AbbVie, Amgen, Celgene, Eli Lilly and Novartis; BG: research grants from Pfizer, Abbvie and BMS; LP: consultant of Novartis Finland, UCB Pharma, Pfizer, Sanofi, BMS, AbbVie, Amgen, Celgene, Eli Lilly, Boehringer-Ingelheim, Mylan; KL: consulting and/or speaking fees from Amgen, Johnson and Johnson and Novartis; ACo: research grants, consulting and/or speaking fees from Amgen, Lilly, Pfizer, Boehringer Ingelheim; KP: speaker and consulting fees from Pfizer, MSD, BMS, UCB, Amgen, Egis, Roche, AbbVie; JZ: speaker and consulting fees from Abbvie, Elli-Lilly, Sandoz, Novartis, Egis, UCB; EKK: none; NA: speaking fees from Pfizer; ÖSG: none; HS: research grant from Sociedade Portuguesa de Reumatologia and speaker and/or consultancy fees from Abbvie, Janssen, Lilly, Novartis and Pfizer; MJN: consulting and/or speaking fees from AbbVie, Eli Lilly, Janssens, Novartis and Pfizer; BM: research grant from Novartis; GTJ: research grants from AbbVie, Pfizer, UCB, Amgen, GSK. Speaker fee from Janssen; HR: consulting and/or speaking fees from Abbvie, Celgene, Pfizer, UCB, and Viatris; MT: consulting and/or speaking fees from Abbvie, Amgen, Biogen, Eli Lilly, Janssen, Medis, MSD, Novartis, Pfizer, Sanofi, Sandoz-Lek; AJG: none; IHB: Consultant for Abbvie, UCB, MSD, Novartis, Lilly, unrestricted Grants received for investigator initiated studies from: MSD, Pfizer, AbbVie, UCB, fees received for Lectures from BMS, AbbVie, Pfizer, MSD ; JA: PI for agreements between Karolinska Institutet and Abbvie, Astra-Zeneca, BMS, Eli Lilly, Janssen, MSD, Pfizer, Roche, Samsung Bioepis, Sanofi, and UCB; FI: consulting and/or speaking from Abbvie, Amgen, AstraZeneca, BMS, Galapagos, Janssen, Lilly, MSD, Novartis, Pfizer, Roche and UCB; AGL: Research Grant from Novartis, and speaker and/or consultancy fees from AbbVie, Janssen, Lilly, MSD, Novartis, Pfizer, Roche, and UCB; ACi: consulting and/or speaking fees from AbbVie, Eli Lilly, Merck Sharp & Dohme, Novartis and Pfizer; MJS: speaker fees from Abbvie, AstraZeneca, Lilly, Novartis and Pfizer; CC: Speaker and consultancy fees from AbbVie, Amgen, Boehringer Ingelheim, Ewopharma, Lilly, Novartis, Pfizer; ZR: speaker or consultancy fees from Abbvie, Novartis, MSD, Medis, Biogen, Eli Lilly, Pfizer, Sanofi, Lek, Janssen; BjG: consulting and/or speaking fees from Amgen and Novartis; MØ: research grants from Abbvie, BMS, Merck, Celgene and Novartis, and speaker and/or consultancy fees from Abbvie, BMS, Boehringer-Ingelheim, Celgene, Eli-Lilly, Hospira, Janssen, Merck, Novartis, Novo, Orion, Pfizer, Regeneron, Roche, Sandoz, Sanofi and UCB; MLH: Research grants from Abbvie, Biogen, BMS, Celltrion, Eli Lilly, Janssen Biologics B.V, Lundbeck Fonden, MSD, Medac, Pfizer, Roche, Samsung Biopies, Sandoz, Novartis. This work was supported by Novartis Pharma AG .

Keywords

Ankylosing spondylitis disease activity score
Axial spondyloarthritis
Predictors
TNF-inhibitors

Access to Document

Ørnbjerg_etal_SAR_Predictors_Of_ASDAS-CRP_VoR
0049-0172/© 2022 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/bync-nd/4.0/).
Final published version, 170 KBLicence: CC BY-NC-ND

Cite this

Ørnbjerg, L. M., Linde, L., Georgiadis, S., Rasmussen, S. H., Lindström, U., Askling, J., Michelsen, B., Giuseppe, D. D., Wallman, J. K., Pavelka, K., Závada, J., Nissen, M. J., Jones, G. T., Relas, H., Pirilä, L., Tomšič, M., Rotar, Z., Geirsson, A. J., Gudbjornsson, B., ... Hetland, M. L. (2022). Predictors of ASDAS-CRP inactive disease in axial spondyloarthritis during treatment with TNF-inhibitors: Data from the EuroSpA collaboration. Seminars in arthritis and rheumatism, 56, Article 152081. https://doi.org/10.1016/j.semarthrit.2022.152081, https://doi.org/10.1016/j.semarthrit.2022.152141

Predictors of ASDAS-CRP inactive disease in axial spondyloarthritis during treatment with TNF-inhibitors: Data from the EuroSpA collaboration. / Ørnbjerg, Lykke M.; Linde, Louise (Corresponding Author); Georgiadis, Stylianos et al.
In: Seminars in arthritis and rheumatism, Vol. 56, 152081, 01.10.2022.

Research output: Contribution to journal › Article › peer-review

Ørnbjerg, LM, Linde, L, Georgiadis, S, Rasmussen, SH, Lindström, U, Askling, J, Michelsen, B, Giuseppe, DD, Wallman, JK, Pavelka, K, Závada, J, Nissen, MJ, Jones, GT, Relas, H, Pirilä, L, Tomšič, M, Rotar, Z, Geirsson, AJ, Gudbjornsson, B, Kristianslund, EK, van sder Horst-Bruinsma, I, Loft, AG, Laas, K, Iannone, F, Corrado, A, Ciurea, A, Santos, MJ, Santos, H, Codreanu, C, Akkoc, N, Gunduz, OS, Glintborg, B, Østergaard, M & Hetland, ML 2022, 'Predictors of ASDAS-CRP inactive disease in axial spondyloarthritis during treatment with TNF-inhibitors: Data from the EuroSpA collaboration', Seminars in arthritis and rheumatism, vol. 56, 152081. https://doi.org/10.1016/j.semarthrit.2022.152081, https://doi.org/10.1016/j.semarthrit.2022.152141

Ørnbjerg LM, Linde L, Georgiadis S, Rasmussen SH, Lindström U, Askling J et al. Predictors of ASDAS-CRP inactive disease in axial spondyloarthritis during treatment with TNF-inhibitors: Data from the EuroSpA collaboration. Seminars in arthritis and rheumatism. 2022 Oct 1;56:152081. Epub 2022 Aug 17. doi: 10.1016/j.semarthrit.2022.152081, 10.1016/j.semarthrit.2022.152141

@article{454672c0f9964c679dc0ee8014c281c6,

title = "Predictors of ASDAS-CRP inactive disease in axial spondyloarthritis during treatment with TNF-inhibitors: Data from the EuroSpA collaboration",

abstract = "Objectives: In patients with axial spondyloarthritis (axSpA) initiating their first tumor necrosis factor alpha-inhibitor (TNFi), we aimed to identify common baseline predictors of Ankylosing Spondylitis Disease Activity Score (ASDAS-CRP) inactive disease (primary objective) and clinically important improvement (CII) at 6 months, and drug retention at 12-months across 15 European registries. Methods: Baseline demographic and clinical characteristics were collected. Outcomes were investigated per registry and in pooled data using logistic regression analyses on multiply imputed data. Results: The consistency of baseline predictors in individual registries justified pooling the data. In the pooled dataset (n = 21,196), the 6-month rates for ASDAS inactive disease and ASDAS CII were 26\% and 51\%, and the 12-month drug retention rate 65\% in patients with available data (n = 9,845, n = 6,948 and n = 21,196, respectively). Nine common baseline predictors of ASDAS inactive disease, ASDAS CII and 12-month drug retention were identified, and the odds ratios (95\%-confidence interval) for ASDAS inactive disease were: age, per year: 0.97 (0.97{\textendash}0.98), men vs. women: 1.88 (1.60{\textendash}2.22), current vs. non-smoking: 0.76 (0.63{\textendash}0.91), HLA-B27 positive vs. negative: 1.51 (1.20{\textendash}1.91), TNF start year 2015{\textendash}2018 vs. 2009{\textendash}2014: 1.24 (1.06{\textendash}1.45), CRP>10 vs. ≤10 mg/l: 1.49 (1.25{\textendash}1.77), one unit increase in health assessment questionnaire (HAQ): 0.77 (0.58{\textendash}1.03), one-millimeter (mm) increase in Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) fatigue and spinal pain: 0.99 (0.99{\textendash}1.00) and 0.99 (0.99{\textendash}1.99), respectively Conclusion: Common baseline predictors of treatment response and adherence to TNFi could be identified across data from 15 European registries, indicating that they may be universal across different axSpA populations.",

keywords = "Ankylosing spondylitis disease activity score, Axial spondyloarthritis, Predictors, TNF-inhibitors",

author = "{\O}rnbjerg, \{Lykke M.\} and Louise Linde and Stylianos Georgiadis and Rasmussen, \{Simon H.\} and Ulf Lindstr{\"o}m and Johan Askling and Brigitte Michelsen and Giuseppe, \{Daniela Di\} and Wallman, \{Johan K.\} and Karel Pavelka and Jakub Z{\'a}vada and Nissen, \{Michael J.\} and Jones, \{Gareth T.\} and Heikki Relas and Laura Piril{\"a} and Matija Tom{\v s}i{\v c} and Ziga Rotar and Geirsson, \{Arni Jon\} and Bjorn Gudbjornsson and Kristianslund, \{Eirik K.\} and \{van sder Horst-Bruinsma\}, Irene and Loft, \{Anne Gitte\} and Karin Laas and Florenzo Iannone and Addolorata Corrado and Adrian Ciurea and Santos, \{Maria J.\} and Helena Santos and Catalin Codreanu and Nurullah Akkoc and Gunduz, \{Ozgul S.\} and Bente Glintborg and Mikkel {\O}stergaard and Hetland, \{Merete Lund\}",

note = "Funding Information This work was supported by Novartis Pharma AG . Acknowledgments The EuroSpA Research Collaboration Network was financially supported by Novartis Pharma AG. Novartis had no influence on the data collection, statistical analyses, manuscript preparation or decision to submit the manuscript. Professor Gary Macfarlane (University of Aberdeen) is Chief Investigator of BSRBR-AS and facilitated access to the UK data used in this study. Corrigendum to {\textquoteleft}Predictors of ASDAS-CRP inactive disease in axial spondyloarthritis during treatment with TNF-inhibitors: data from the EuroSpA collaboration{\textquoteright} [Seminars in Arthritis and Rheumatism 56 (2022) 1-13/152081] https://doi.org/10.1016/j.semarthrit.2022.152141",

year = "2022",

month = oct,

day = "1",

doi = "10.1016/j.semarthrit.2022.152081",

language = "English",

volume = "56",

journal = "Seminars in arthritis and rheumatism",

issn = "0049-0172",

publisher = "W.B. Saunders",

}

TY - JOUR

T1 - Predictors of ASDAS-CRP inactive disease in axial spondyloarthritis during treatment with TNF-inhibitors

T2 - Data from the EuroSpA collaboration

AU - Ørnbjerg, Lykke M.

AU - Linde, Louise

AU - Georgiadis, Stylianos

AU - Rasmussen, Simon H.

AU - Lindström, Ulf

AU - Askling, Johan

AU - Michelsen, Brigitte

AU - Giuseppe, Daniela Di

AU - Wallman, Johan K.

AU - Pavelka, Karel

AU - Závada, Jakub

AU - Nissen, Michael J.

AU - Jones, Gareth T.

AU - Relas, Heikki

AU - Pirilä, Laura

AU - Tomšič, Matija

AU - Rotar, Ziga

AU - Geirsson, Arni Jon

AU - Gudbjornsson, Bjorn

AU - Kristianslund, Eirik K.

AU - van sder Horst-Bruinsma, Irene

AU - Loft, Anne Gitte

AU - Laas, Karin

AU - Iannone, Florenzo

AU - Corrado, Addolorata

AU - Ciurea, Adrian

AU - Santos, Maria J.

AU - Santos, Helena

AU - Codreanu, Catalin

AU - Akkoc, Nurullah

AU - Gunduz, Ozgul S.

AU - Glintborg, Bente

AU - Østergaard, Mikkel

AU - Hetland, Merete Lund

N1 - Funding Information This work was supported by Novartis Pharma AG . Acknowledgments The EuroSpA Research Collaboration Network was financially supported by Novartis Pharma AG. Novartis had no influence on the data collection, statistical analyses, manuscript preparation or decision to submit the manuscript. Professor Gary Macfarlane (University of Aberdeen) is Chief Investigator of BSRBR-AS and facilitated access to the UK data used in this study. Corrigendum to ‘Predictors of ASDAS-CRP inactive disease in axial spondyloarthritis during treatment with TNF-inhibitors: data from the EuroSpA collaboration’ [Seminars in Arthritis and Rheumatism 56 (2022) 1-13/152081] https://doi.org/10.1016/j.semarthrit.2022.152141

PY - 2022/10/1

Y1 - 2022/10/1

N2 - Objectives: In patients with axial spondyloarthritis (axSpA) initiating their first tumor necrosis factor alpha-inhibitor (TNFi), we aimed to identify common baseline predictors of Ankylosing Spondylitis Disease Activity Score (ASDAS-CRP) inactive disease (primary objective) and clinically important improvement (CII) at 6 months, and drug retention at 12-months across 15 European registries. Methods: Baseline demographic and clinical characteristics were collected. Outcomes were investigated per registry and in pooled data using logistic regression analyses on multiply imputed data. Results: The consistency of baseline predictors in individual registries justified pooling the data. In the pooled dataset (n = 21,196), the 6-month rates for ASDAS inactive disease and ASDAS CII were 26% and 51%, and the 12-month drug retention rate 65% in patients with available data (n = 9,845, n = 6,948 and n = 21,196, respectively). Nine common baseline predictors of ASDAS inactive disease, ASDAS CII and 12-month drug retention were identified, and the odds ratios (95%-confidence interval) for ASDAS inactive disease were: age, per year: 0.97 (0.97–0.98), men vs. women: 1.88 (1.60–2.22), current vs. non-smoking: 0.76 (0.63–0.91), HLA-B27 positive vs. negative: 1.51 (1.20–1.91), TNF start year 2015–2018 vs. 2009–2014: 1.24 (1.06–1.45), CRP>10 vs. ≤10 mg/l: 1.49 (1.25–1.77), one unit increase in health assessment questionnaire (HAQ): 0.77 (0.58–1.03), one-millimeter (mm) increase in Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) fatigue and spinal pain: 0.99 (0.99–1.00) and 0.99 (0.99–1.99), respectively Conclusion: Common baseline predictors of treatment response and adherence to TNFi could be identified across data from 15 European registries, indicating that they may be universal across different axSpA populations.

AB - Objectives: In patients with axial spondyloarthritis (axSpA) initiating their first tumor necrosis factor alpha-inhibitor (TNFi), we aimed to identify common baseline predictors of Ankylosing Spondylitis Disease Activity Score (ASDAS-CRP) inactive disease (primary objective) and clinically important improvement (CII) at 6 months, and drug retention at 12-months across 15 European registries. Methods: Baseline demographic and clinical characteristics were collected. Outcomes were investigated per registry and in pooled data using logistic regression analyses on multiply imputed data. Results: The consistency of baseline predictors in individual registries justified pooling the data. In the pooled dataset (n = 21,196), the 6-month rates for ASDAS inactive disease and ASDAS CII were 26% and 51%, and the 12-month drug retention rate 65% in patients with available data (n = 9,845, n = 6,948 and n = 21,196, respectively). Nine common baseline predictors of ASDAS inactive disease, ASDAS CII and 12-month drug retention were identified, and the odds ratios (95%-confidence interval) for ASDAS inactive disease were: age, per year: 0.97 (0.97–0.98), men vs. women: 1.88 (1.60–2.22), current vs. non-smoking: 0.76 (0.63–0.91), HLA-B27 positive vs. negative: 1.51 (1.20–1.91), TNF start year 2015–2018 vs. 2009–2014: 1.24 (1.06–1.45), CRP>10 vs. ≤10 mg/l: 1.49 (1.25–1.77), one unit increase in health assessment questionnaire (HAQ): 0.77 (0.58–1.03), one-millimeter (mm) increase in Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) fatigue and spinal pain: 0.99 (0.99–1.00) and 0.99 (0.99–1.99), respectively Conclusion: Common baseline predictors of treatment response and adherence to TNFi could be identified across data from 15 European registries, indicating that they may be universal across different axSpA populations.

KW - Ankylosing spondylitis disease activity score

KW - Axial spondyloarthritis

KW - Predictors

KW - TNF-inhibitors

UR - https://www.scopus.com/pages/publications/85135923596

U2 - 10.1016/j.semarthrit.2022.152081

DO - 10.1016/j.semarthrit.2022.152081

M3 - Article

C2 - 35985172

AN - SCOPUS:85135923596

SN - 0049-0172

VL - 56

JO - Seminars in arthritis and rheumatism

JF - Seminars in arthritis and rheumatism

M1 - 152081

ER -

Predictors of ASDAS-CRP inactive disease in axial spondyloarthritis during treatment with TNF-inhibitors: Data from the EuroSpA collaboration

Abstract

Bibliographical note

Data Availability Statement

Funding

Keywords

Access to Document

Other files and links

Fingerprint

Cite this